文献速递治疗药物监测与药物基因组学

治疗药物监测教育现状:范围综述与全球问卷调查

Therapeutic drug monitoring education: The current state.
PubMed 文献 · Br J Clin Pharmacol · 2025-08-26

本研究分两阶段:先对TDM教育项目文献进行范围综述,再向全球TDM专业网络发放问卷。共找到8篇文献,收到23份回复(回复率30%),其中68%来自学术界。70%受访者所在地区将TDM纳入医护人员教育,56%在本科和研究生阶段均提供,主要面向医师(39%)和药师(65%)。TDM教育分散于不同学科和学位,缺乏通用指南。

要点

  • TDM教育分散于不同学科和学位,缺乏通用指南。
  • TDM教育主要面向医师和药师,经费主要来自公共来源。
  • TDM实践主要集中在感染性疾病、神经病学和精神病学。

核心结论

  • TDM教育分散于不同学科、学位和课程中,主要面向医师和药师,经费以公共来源为主,且缺乏通用指南。

研究设计与样本

  • 研究分两阶段:先对TDM教育项目相关科学文献进行范围综述,再向全球TDM专业网络发放问卷。
  • 共找到8篇讨论TDM教育项目的科学文章,问卷收到23份回复(回复率30%),其中68%来自学术界。

主要发现

  • 8篇文章深入描述了一个TDM教育项目,该项目主要作为医院工作人员的研究生教育项目提供。
  • 70%受访者报告TDM是医护人员教育项目的一部分,56%在本科和研究生阶段均提供,主要面向医师(39%)和药师(65%)。
  • TDM主要应用于感染性疾病(n=15)、神经病学(n=14)和精神病学(n=12),以及抗生素(83%)、单克隆抗体(53%)、肿瘤和精神病药物(48%)。
  • TDM经费主要来自公共健康保险(48%)、医院(44%)、患者(39%),部分情况下患者可能向医院或健康保险基金共付。

临床怎么用

  • 临床药学智能体医生应认识到TDM教育背景分散,需结合当地教育项目和指南开展实践。
  • 关注TDM在感染性疾病、神经病学和精神病学等重点领域的应用。

局限性

  • 问卷回复率仅30%,样本量较小(23份),代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate available information on therapeutic drug monitoring (TDM) education programmes and their implementation across different countries. METHODS: The study was performed in two phases. First, a scoping review of scientific literature on available education programmes was performed. Afterwards, a questionnaire was distributed among a worldwide network of professionals engaged in the practice of TDM. RESULTS: Eight scientific articles discussing TDM educational programmes were found. They described in depth an educational programme on TDM, which was primarily offered as postgraduate education programme for hospital staff. We received a total 23 responses (30% response rate); of these, 68% were from academia. For 70% of respondents, TDM is part of the educational programme of healthcare professionals, and for 56% it is offered at both undergraduate and postgraduate level, aimed mainly at physicians (39%) and pharmacists (65%). TDM is mainly performed in infectious diseases (n = 15), neurology (n = 14) and psychiatry (n = 12), as well as for antibiotics (83%), monoclonal antibodies (53%), and oncology and psychotropics (48%). Funding for TDM is derived mostly from public health insurance (48%), hospital (44%), patients (39%). In some cases, patients might co-pay to hospital or to health insurance fund. CONCLUSIONS: Education on TDM is scattered across different subjects, disciplines and degrees. It is oriented essentially towards physicians and pharmacists, and its funding is mainly public. General guidelines are lacking. In light of this, it is necessary to consider developing a comprehensive educational programme on TDM, oriented towards relevant drugs and diseases, and encompassing appropriate analytical and pharmacological methods.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Petrova G, Blagova S, Tachkov K, et al. Therapeutic drug monitoring education: The current state. Br J Clin Pharmacol. 2025. PMID: 40859674. doi:10.1002/bcp.70252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。